Compare Blackstone Inc (BX) vs TG Therapeutics Inc (TGTX) Price & Performance

Blackstone (BX) trades at $146.44, up 3.37% today, near its recent high. The stock shows strong earnings momentum with three consecutive quarterly beats and a robust 25.85% net income margin. Technical indicators are bullish overall, though RSI levels suggest potential overbought conditions. Recent corporate activity includes a $2.5 billion investment in Air Canada's Aeroplan loyalty program, highlighting aggressive growth initiatives.

The outlook remains positive given consistent earnings outperformance and strategic acquisitions. Key risks include market sensitivity to private equity cycles and high valuation multiples. With a consensus price target of $144.00 and 63% analyst buy ratings, Wall Street sentiment is bullish, but investors should monitor execution on large deals and broader economic trends.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.